SPPI
Price:
$1.025
Market Cap:
$210.38M
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license...[Read more]
Industry
Biotechnology
IPO Date
1996-09-26
Stock Exchange
NASDAQ
Ticker
SPPI
According to Spectrum Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.85. This represents a change of 0.33% compared to the average of -2.84 of the last 4 quarters.
The mean historical PE Ratio of Spectrum Pharmaceuticals, Inc. over the last ten years is -6.36. The current -2.85 PE Ratio has changed 4.37% with respect to the historical average. Over the past ten years (40 quarters), SPPI's PE Ratio was at its highest in in the June 2018 quarter at 39.12. The PE Ratio was at its lowest in in the June 2015 quarter at -47.72.
Average
-6.36
Median
-6.12
Minimum
-17.68
Maximum
-0.86
Discovering the peaks and valleys of Spectrum Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 275.39%
Maximum Annual PE Ratio = -0.86
Minimum Annual Increase = -224.78%
Minimum Annual PE Ratio = -17.68
Year | PE Ratio | Change |
---|---|---|
2022 | -0.86 | -30.36% |
2021 | -1.24 | -49.88% |
2020 | -2.48 | -16.71% |
2019 | -2.97 | -60.53% |
2018 | -7.53 | -57.39% |
2017 | -17.68 | 275.39% |
2016 | -4.71 | -38.88% |
2015 | -7.70 | -21.46% |
2014 | -9.81 | 13.39% |
2013 | -8.65 | -224.78% |
The current PE Ratio of Spectrum Pharmaceuticals, Inc. (SPPI) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.53
5-year avg
-3.02
10-year avg
-6.36
Spectrum Pharmaceuticals, Inc.’s PE Ratio is greater than Selecta Biosciences, Inc. (-3.39), greater than Paratek Pharmaceuticals, Inc. (-3.05), greater than Corvus Pharmaceuticals, Inc. (-10.64), greater than Immutep Limited (-74.70), greater than Icosavax, Inc. (-8.27), greater than Ardelyx, Inc. (-20.16), greater than Zura Bio Limited (-9.00), less than Hepion Pharmaceuticals, Inc. (-0.15), less than AVROBIO, Inc. (2.07), less than Verastem, Inc. (-0.72), greater than Agios Pharmaceuticals, Inc. (-6.74), less than bluebird bio, Inc. (-0.52), greater than Intercept Pharmaceuticals, Inc. (-13.55), less than Karyopharm Therapeutics Inc. (-0.98), less than BioLineRx Ltd. (0), less than Lexicon Pharmaceuticals, Inc. (-1.63), less than Seres Therapeutics, Inc. (-2.49), less than ImmunityBio, Inc. (-0.89), greater than Gamida Cell Ltd. (-3.88), less than Rigel Pharmaceuticals, Inc. (-0.23), greater than Geron Corporation (-16.42), greater than ImmunoGen, Inc. (-12.66), greater than null (-122.93),
Company | PE Ratio | Market cap |
---|---|---|
-3.39 | $135.20M | |
-3.05 | $127.83M | |
-10.64 | $252.08M | |
-74.70 | $382.21M | |
-8.27 | $769.04M | |
-20.16 | $1.32B | |
-9.00 | $230.86M | |
-0.15 | $4.20M | |
2.07 | $5.24M | |
-0.72 | $96.58M | |
-6.74 | $2.46B | |
-0.52 | $101.94M | |
-13.55 | $794.69M | |
-0.98 | $91.04M | |
0 | $55.61M | |
-1.63 | $582.00M | |
-2.49 | $145.36M | |
-0.89 | $2.35B | |
-3.88 | $4.34M | |
-0.23 | $234.37M | |
-16.42 | $2.56B | |
-12.66 | $8.73B | |
-122.93 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Spectrum Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Spectrum Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Spectrum Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Spectrum Pharmaceuticals, Inc. (SPPI)?
What is the highest PE Ratio for Spectrum Pharmaceuticals, Inc. (SPPI)?
What is the 3-year average PE Ratio for Spectrum Pharmaceuticals, Inc. (SPPI)?
What is the 5-year average PE Ratio for Spectrum Pharmaceuticals, Inc. (SPPI)?
How does the current PE Ratio for Spectrum Pharmaceuticals, Inc. (SPPI) compare to its historical average?